Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities

Inclusion Criteria: * Adult \>18 years diagnosed with HIV by standard microbiological techniques * Active antiretroviral treatment with DTG/3TC * Last HIV viral load performed on the participant in the 6 months prior to the visit screening \< 50 copies/mL. If the participant does not have an HIV viral load \<50 cop/mL performed in the 14 days prior to the screening visit, it will be necessary to confirm at screening visit that the participant's HIV viral load is \<50 cop/mL * Prior clinical diagnosis, carried out by a qualified specialist physician, of any of the following pathologies: Insomnia Anxiety disorders Depressive disorders Exclusion Criteria: * Allergy or intolerance to any of the components of BIC/FTC/TAF * History of active CNS infections * Active psychosis or suicidal ideation * Pregnant or lactating women, as well as women of childbearing age who do not commit to use at least two contraceptive methods * Any clinical or laboratory condition that in the opinion of the investigator will prevent the participant to complete the study procedures * Participant included in the neuroimaging substudy: Claustrophobia or presence of magnetizable body devices